A Review on Development for Sterile Liquid Product Blow Fill Seal Pack

which like pneumonic delivery, plastic a For medical specialty that area unit administered by sure ways in ampoules offers several and points over glass ampoules, vials, or syringes. Plastic ampoules area unit manufacture victimisation blow–fill–seal (BFS) technology. within the BFS method plastic extrusion, molding, antiseptic filling in one line operation. The in operation conditions for a BFS method and therefore the nature of plastic ampoules provides several issues to the steadiness and integrity of biological drug product. Blow-Fill-Seal (BFS) technology is an advanced aseptic manufacturing process widely used in the pharmaceutical, healthcare, cosmetic, and food industries for the production of sterile liquid products. The BFS machine integrates container formation, product filling, and container sealing into a single continuous automated operation, minimizing human intervention and reducing the risk of contamination. In this process, thermoplastic resin is extruded into a container, which is immediately filled with the product and hermetically sealed under sterile conditions. BFS technology is recognized as an advanced aseptic processing method because it provides high sterility assurance, operational efficiency, and cost-effective production

BFStechnology, Blow-Fill-Sealmachine, Aseptic packaging machinery

1. US Pharmacopoeia: bacterial endotoxins test, Chapter. 85, http://www.pharmacopeia.cn/v29240/usp29nf2 4s0_c85.html [Google Scholar] [Crossref]

2. US Pharmacopoeia: Good manufacturing practices for bulk pharmaceutical excipients, Chapter 1078, US Pharmacopoeia: Good repackaging practices, Chapter 1178 [Google Scholar] [Crossref]

3. US Pharmacopoeia: “Sterile product packaging—integrity evaluation”, Chapter 1207, [8] WHO Good Manufacturing Practices: water for pharmaceutical use, World Health Organization WHO Technical Report Series, No. 929, 2005Annex 3 [Google Scholar] [Crossref]

4. US Pharmacopoeia: “water for pharmaceutical purposes”, Chapter1231 [10] F. Leo, P. Poisson, C.S. Sinclair, and A. Tallentire, PDA J. Pharm. Sci. Technol. 58 [Google Scholar] [Crossref]

5. US Pharmacopoeia: “water for pharmaceutical purposes”,Chapter1231,http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1231.html [20] W. A. Helbig, (1946)Activated carbon, J. Chem. Educ., 23 (2), p 98. [21] US:PH,Chapter791,://www.pharmacopeia.cn/v29240/usp29nf24s0_c791.html [Google Scholar] [Crossref]

6. Niazi, Sarfaraz K. (2020), Handbook of Pharmaceutical Manufacturing Formulations – Volume 6: Sterile Products (3rd ed.), Boca Raton London New York: CRC Press, , p. 33 [Google Scholar] [Crossref]

7. Steinborn, Leonhard (2005), GMP/ISO Quality Audit Manual for Healthcare Manufacturers and Their Suppliers – Volume 2: Regulations, Standards, and Guidelines (6th ed.), Boca Raton London New York Washington, D.C.: CRC Press, [Google Scholar] [Crossref]

8. Sinclair, C S (1995). (PDF). PDA-Journal of Pharmaceutical Science and Technology. (6): 494–499. Retrieved 24 March 2021. [Google Scholar] [Crossref]

9. Bradley, A (July 1991), (PDF), Journal of Parenteral Science and Technology, (4): 187–194, retrieved 25 March 2021 [Google Scholar] [Crossref]

10. Flickinger, Michael C. (2013), Downstream Industrial Biotechnology – Recovery and Purification, Hoboken: Wiley, p. 703 [Google Scholar] [Crossref]

11. Thielen, Michael (2021), Extrusion Blow Molding, Carl Hanser Verlag, p. 139 [Google Scholar] [Crossref]

12. Gibson, Mark (2009), Pharmaceutical Preformulation and Formulation (2nd ed.), Newy York London: informa healthcare, p. 339 [Google Scholar] [Crossref]

13. Spalding, Mark A.; Chatterjee, Ananda M. (2018), Handbook of Industrial Polyethylene and Technology (1st ed.), Beverly: Scrivener Publishing, p. 1103 [Google Scholar] [Crossref]

14. Downey, K.; Haerer, M.; Marguillier, S.; Åkerman, P. (2016), The Manufacture of Sterile Pharmaceuticals and Liquid Medical Devices Using Blow-Fill-Seal Technology · Points to Consider (1st ed.), Editio-Cantor-Verlag, p. 64, [Google Scholar] [Crossref]

15. Amin, A.; Chauhan, S.; Dare, M.; Bansal, A. K. (2012), "Sorption of antimicrobial agentsinblow-fill-sealpacks", PharmaceuticalDevelopmentandTechnology, informationhealthcare: 8 [Google Scholar] [Crossref]

16. Gad, Shayne Cox (2008), Pharmaceutical Manufacturing Handbook – Production and Processes, Hoboken: Wiley, , p. 103 [Google Scholar] [Crossref]

17. das Nevas, José; Sarmento, Bruno (2014), Mucosal Delivery of Biopharmaceuticals – Biology, Challenges and Strategies, New York Heidelberg Dordrecht London: Springer, p. 444 [Google Scholar] [Crossref]

18. Vasile, Cornelia; Pascu, Mihaela (2005), Practical Guide to Polyethylene, Shawbury: Rapra Technology Limited, p. 124 [Google Scholar] [Crossref]

19. Flickinger, Michael C. (2013), Downstream Industrial Biotechnology – Recovery and Purification, Hoboken: Wiley, p. 703 [Google Scholar] [Crossref]

20. Amin, A.; Sangamwar, A.; Dare, M.; Bansal, A. K. (2012), "Interaction of antimicrobial preservatives with blow-fill-seal packs: correlating sorption with solubility parameters", Pharmaceutical Development and Technology, (5), informa healthcare: 614–624, [Google Scholar] [Crossref]

21. Spalding, Mark A.; Chatterjee, Ananda M. (2018), Handbook of Industrial Polyethylene and Technology (1st ed.), Beverly: Scrivener Publishing, p. 1104 [Google Scholar] [Crossref]

22. Thielen, Michael (2021), Extrusion Blow Molding, Carl Hanser Verlag, p. 139 [Google Scholar] [Crossref]

23. Swarbrick, James; Boylan, James C. (2001), Encyclopedia of Pharmaceutical Technology – Volume 20, New York · Basel: Marcel Dekker, p. 1 [Google Scholar] [Crossref]

24. Oschmann, R.; Schubert, O. E. (1999), Blow-Fill-Seal Technology, vol. 40, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH – CRC Press Inc. [Google Scholar] [Crossref]

25. Rosato, Dominick V.; Rosato, Donald V.; Rosato, Matthew V. (2005), Plastic Product Material and Process Selection Handbook, Elsevier Science & Technology Books [Google Scholar] [Crossref]

26. Swarbrick, James; Boylan, James C. (2001), Encyclopedia of Pharmaceutical Technology – Volume 20, New York · Basel: Marcel Dekker, [Google Scholar] [Crossref]

27. Dean, D. A.; Evans, E. R.; Hall, I. H. (2000), Pharmaceutical Packaging Technology, London New York: Taylor & Francis, p. 438 [Google Scholar] [Crossref]

28. Oschmann, R.; Schubert, O. E. (1999), Blow-Fill-Seal Technology, vol. 40, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH – CRC Press Inc., p. 23, [Google Scholar] [Crossref]

29. Nema, Sandeep; Ludwig, John D. (2010), Pharmaceutical Dosage Forms: Parental Medications – Volume 3: Regulations, Validation and the Future (3rd ed.), New York, London: informa healthcare, p. 7 [Google Scholar] [Crossref]

30. Swarbrick, James; Boylan, James C. (2001), Encyclopedia of Pharmaceutical Technology – Volume 20, New York · Basel: Marcel Dekker, p. 2 [Google Scholar] [Crossref]

31. Jornitz, Maik W. (2020), Filtration and Purification in the Biopharmaceutical Industry (3rd ed.), Boca Raton London New York: CRC Press, p. 539 [Google Scholar] [Crossref]

32. Gibson, Mark (2009), Pharmaceutical Preformulation and Formulation (2nd ed.), Newy York London: informa healthcare, p. 339 [Google Scholar] [Crossref]

33. Denyer, Stephen P.; Hodges, Norman; Gorman, Sean P.; Gilmore, Brendan F. (2011), Hugo and Russell's Pharmaceutical Microbiology, Chichester: Wiley-Blackwell, p. 387 [Google Scholar] [Crossref]

34. Amin, A.; Chauhan, S.; Dare, M.; Bansal, A. K. (2012), "Sorption of antimicrobial agents in blow-fill-seal packs", Pharmaceutical Development and Technology, (1), informa healthcare: 84–93, [Google Scholar] [Crossref]

35. Oschmann, R.; Schubert, O. E. (1999), Blow-Fill-Seal Technology, vol. 40, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH – CRC Press Inc., p. 81, [Google Scholar] [Crossref]

36. Groves, Michael J.; Murty, Ram (1995), Aseptic Pharmaceutical Manufacturing II – Applications for the 1990s, Boca Raton London New York: CRC Press, p. 364 [Google Scholar] [Crossref]

37. Swarbrick, James; Boylan, James C. (2001), Encyclopedia of Pharmaceutical Technology – Volume 20, New York · Basel: Marcel Dekker, p. 10 [Google Scholar] [Crossref]

38. Gail, Lothar; Gommel, Udo (2018), Reinraumtechnik (in German) (4th ed.), Berlin: Springer, p. 604 [Google Scholar] [Crossref]

39. Sandle, Tim (2016), Pharmaceutical Microbiology – Essentials for Quality Assurance and Quality Control, Cambridge: Woodhead Publishing Limited, p. 154 [Google Scholar] [Crossref]

40. Hardee, Gregory E.; Baggot, J. Desmond (1998), Development and Formulation of Veterinary Dosage Forms – Drugs and the Pharmaceutical Sciences (2nd ed.), New York · Basel · Hong Kong: Marcel Dekker, p. 208 [Google Scholar] [Crossref]

41. FDA, Guidance for Industry. Sterile Drug Products Produced by Aseptic Processing— Current Good Manufacturing Practice (Rockville, MD, Sept. 2004) [Google Scholar] [Crossref]

42. European Commission, EU Guidelines to Good Manufacturing Practice. Annex 1, Manufacture of Sterile Medicinal Products (Brussels, Nov. 2008). [Google Scholar] [Crossref]

43. S.J. Shire, "Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme (Dornase Alpha)]," in Formulation, Characterization and Stability of Protein Drugs: Case Histories, R. Perlman, and Y.J. Wang, Eds. (Plenum Press, New York and London, 1996) pp. 393–426. [Google Scholar] [Crossref]

44. M.H.V. van Regenmortel, K. Boven, and F. Bader, BioPharm Int. 18 (8), 36–50 (2005). [Google Scholar] [Crossref]

45. FDA, Guidance for Industry: Container Cosure Systems for Packaging Human Drugs and Biologics (Rockville, MD, May 1999). [Google Scholar] [Crossref]

46. C.J. Taborsky, E.B. Sheinin, and D.G. Hunt, Am.Pharm. Rev. 9 (6), 146–150 (2006). [Google Scholar] [Crossref]

47. European Commission, EU Guidelines to Good Manufacturing Practice. Annex 1, Manufacture of Sterile Medicinal Products (Brussels, Nov. 2008). [Google Scholar] [Crossref]

48. W. Whyte et al., PDA J. Pharm. Sci. Technol. 52 (3), 89–99 (1998). [13] B. Ljungqvist et al., PDA J. Pharm. Sci. Technol. 60 (4), 254–258 (2006). [Google Scholar] [Crossref]

49. S.J. Shire, \"Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme (Dornase Alpha)],\" in Formulation, Characterization and Stability of Protein Drugs: Case Histories, R. Perlman, and Y.J. Wang, Eds. (Plenum Press, New York and London, 1996) pp. 393–426. [Google Scholar] [Crossref]

50. US Pharmacopoeia: Sterility Tests, Chapter71 [16] A. Bradley, S. P. Probert, C. S. Sinclair, and A. Tallentire. (1991) Airborne Microbial Challenges of Blow/Fill/Seal Equipment, J. Paren. Sci. Technol., 45 [Google Scholar] [Crossref]

51. M. Sadeghi. Technology Circle Columbia, SC 29203 Tel: (803) 806-3300 V. P. R&D Holopack International Corp. [Google Scholar] [Crossref]

52. Wei Liu, Scott Faulhaber, Samir U. Sane, Philippe Lam BioPharm International, BioPharm International-07-01-2011, Volume 24, Issue 7 [Google Scholar] [Crossref]

53. pharmaceuticalpurposes”,Chapter1231,http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1231.html [20] W. A. Helbig, (1946)Activated carbon, J. Chem. Educ., 23 [Google Scholar] [Crossref]

54. US:PH Chapter791,//www.pharmacopeia.cn/v29240/usp29nf24s0_c791.html Kah Y. Ee, Jian Zhao, Ata-ur Rehman and Samson O. Agboola (2009) Purification and Characterization of a Kunitz-Type Trypsin Inhibitor from Acacia victoriae Bentham Seeds, J. Agric. Food Chem. [Google Scholar] [Crossref]

55. pp 7022–7029. [23] US Pharmacopoeia: bacterial endotoxins test, Chapter. 85, http://www.pharmacopeia.cn/v29240/usp29nf24s0_c85.html [24] Seymour S. Kremen (1975) [Google Scholar] [Crossref]

56. US Pharmacopoeia: bacterial endotoxins test, Chapter. 85, http://www.pharmacopeia.cn/v29240/usp29nf2 4s0_c85.html [Google Scholar] [Crossref]

57. US Pharmacopoeia: Good manufacturing practices for bulk pharmaceutical excipients, Chapter 1078, [Google Scholar] [Crossref]

58. US Pharmacopoeia: Good repackaging practices, Chapter 1178, [Google Scholar] [Crossref]

59. US Pharmacopoeia: “Sterile product packaging—integrity evaluation”, Chapter 1207 [Google Scholar] [Crossref]

60. WHO Good Manufacturing Practices: water for pharmaceutical use, World Health Organization WHO Technical Report Series, No. 929, 2005Annex 3 [Google Scholar] [Crossref]

61. US Pharmacopoeia: “water for pharmaceutical purposes”, Chapter1231 [Google Scholar] [Crossref]

62. F. Leo, P. Poisson, C.S. Sinclair, and A. Tallentire, PDA J. Pharm. Sci. Technol. 58 (3), 147–158 (2010 [Google Scholar] [Crossref]

63. European Commission, EU Guidelines to Good Manufacturing Practice. Annex 1 of Sterile Medicinal Products (Brussels, Nov. 2008). [Google Scholar] [Crossref]

64. W. Whyte et al., PDA J. Pharm. Sci. Technol. 52 (3), 89–99 (1998). [Google Scholar] [Crossref]

65. B. Ljungqvist et al., PDA J. Pharm. Sci. Technol. 60 (4), 254–258 (2006). [Google Scholar] [Crossref]

66. S.J. Shire, "Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme (Dornase Alpha)]," in Formulation, Characterization and Stability of Protein Drugs: Case Histories, R. Perlman, and Y.J. Wang, Eds. (Plenum Press, New York and London, 1996) pp. 393–426. [Google Scholar] [Crossref]

67. US Pharmacopoeia: Sterility Tests, Chapter71 [Google Scholar] [Crossref]

68. A. Bradley, S. P. Probert, C. S. Sinclair, and A. Tallentire. (1991) Airborne Microbial Challenges of Blow/Fill/Seal Equipment, J. Paren. Sci. Technol., 45 (4) 187–192 [Google Scholar] [Crossref]

69. M. Sadeghi. Technology Circle Columbia, SC 29203 Tel: (803) 806-3300 V. P. R&D Holopack International Corp. [Google Scholar] [Crossref]

70. Wei Liu, Scott Faulhaber, Samir U. Sane, Philippe Lam BioPharm International, BioPharm International-07-01-2011, Volume 24, Issue 7 [Google Scholar] [Crossref]

71. US Pharmacopoeia: “water for pharmaceutical purposes”,Chapter1231,http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1231.html [Google Scholar] [Crossref]

72. W. A. Helbig, (1946)Activated carbon, J. Chem. Educ., 23 (2), p 98. [Google Scholar] [Crossref]

• QbD Approach to Hplc Method Development and Validation of the Simultaneous Estimation of Sulbactum and Durlobactum in Pharmaceutical Dosage Form
• A Review on an Evaluation of a Liposomal Hydrogel for Combined Minoxidil and Tretinoin Delivery in Androgenetic Alopecia
• Qualitative Screening and Analysis of Lunasia amara Blanco (Tawal-ulad) Ethanolic Leaves Extract as Potential Anti-Angiogenic Inhibitors Using the Chorioallantoic Membrane Assay on Mallard Duck Embryo
• A Comprehensive Review on Calotropis Procera on Its Analgesic Activity
• Formulation, Characterization and In-Vitro Evaluation of Curcumin Loaded Liposome for Colon Drug delivery